In this systematic review, we sought to summarize the vaccine effectiveness (VE) of observational studies with study periods in which JN.1 (including BA.2.86) or later Omicron subvariants were predominant (≥50%), between January 2024-De

The VIEW-hub Report captures changes in introduction status and use for the vaccines monitored on VIEW-hub made between July 2026–September 2026, including newly added hexavalent vaccines.

The VIEW-hub Report captures changes in introduction status and use for the vaccines monitored on VIEW-hub made between April 2026–July 2026, including updated coverage and access estimates reflecting updated WUENIC data.

Methods document for the literature review of respiratory syncytial virus (RSV) disease burden studies in LMICs presented on VIEW-Hub.

The VIEW-hub Report captures changes in introduction status and use for the vaccines monitored on VIEW-hub made between February 10, 2026–April 30, 2026, including newly added RSV prevention products.

This table shows the serotypes covered by the current pneumococcal conjugate vaccine products. 

This document outlines the methods used in the VIEW-hub data collection and data update process.

The VIEW-hub Report captures changes in introduction status and use for the vaccines monitored on VIEW-hub made between October 27, 2025–February 10, 2026, including newly added malaria vaccines.

Filterable spreadsheets of vaccine effectiveness studies included in the weekly summary tables. Separate spreadsheets are available for primary series and booster dose studies.

This table summarizes the vaccine effectiveness data for COVID-19 studies conducted globally. This table was last updated January 2026.